Back to search

Peptide record

TPDB63529

SynB1 Synb1-ELP Synb1-ELP-PKI Synb1-ELP-TRTK Blood-Brain Barrier Cell-penetrating Peptides standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB63529
SynB1 Synb1-ELP Synb1-ELP-PKI Synb1-ELP-TRTK
Blood-Brain Barrier Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
B3Pred BBPpredict Peptipedia CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP
standard
No
A 18-aa standard natural multi-activity (Blood-Brain Barrier and Cell-penetrating Peptides) peptide sequence curated from B3Pred, BBPpredict, Peptipedia, and other sources, with an available 3D structural model.
Sequence
RGGRLSYSRRRFSTSTGR
Physicochemical Analysis
C86H146N36O26
ANDCEQHIKMPWV
R
2100.33
12.70
6
0
3
+6
3.06
-1.528
21.67
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
70.94
7
Residue Composition
number
0
A
6
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
0
I
1
L
0
K
0
M
1
F
0
P
4
S
2
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 0 L: 1 K: 0 M: 0 F: 1 P: 0 S: 4 T: 2 W: 0 Y: 1 V: 0
Chemical Descriptors
18
C86H146N36O26
2100.33
12.70
+6
3.06
-1.528
Free
L
Linear
Free
Similarity
N[C@@H](CCCN=C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](Cc1ccccc1)C(=O)/N=C/C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 5 records
Evidence 1 Activity

Activity

Blood-Brain Barrier

Target

In situ brain perfusion technique

Assay & Model

Capillary depletion method
Vectorization of dox led to a 20-fold increase in the amount of dox transportation.
Origin/Source
2.5 mg/kg
Capillary depletion method
It led to a significant increase in brain dox concentrations during the first 30 min of postadminist

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
The use of these peptide vectors for brain delivery of dox.
Transcytosis
Brain parenchyma
Combined with Doxorubicin
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

Green fluorescent protein (GFP)-ATXN1[82Q] expressing HEK cells

Assay & Model

3-week-old WT mice
3-week-old WT mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
Peptide (PKA inhibitory peptide)
In vitro and in vivo
CCCCCCCCTTCCCCCCCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

Green fluorescent protein (GFP)-ATXN1[82Q] expressing HEK cells

Assay & Model

3-week-old WT mice
3-week-old WT mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Synthetic
Fluorophore (Rhodamine)
Nucleus
In vitro and in vivo
CCCCCCCCTTCCCCCCCC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

Green fluorescent protein (GFP)-ATXN1[82Q] expressing HEK cells

Assay & Model

3-week-old WT mice
3-week-old WT mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Synthetic
Peptide (S100B inhibitory peptide)
Nucleus
In vitro and in vivo
CCCCCCCCTTCCCCCCCC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

MCF-7, HeLa , MCF-10A , MDA-MB-231 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Rhodamine-labeled Elastin like polypeptide (ELP) loaded p50
Cytoplasm And Nuclear Periphery
At 42°C, the pervasive cytoplasmic distribution indicates that SynB1-ELP1-p50 is efficiently taken up into cells and quickly released into the cytoplasm.
In vitro
CCTTSSCCCCC
Additional Detail Fields 2 fields
CCCCCCCCTTCCCCCCCC CCTTSSCCCCC
Intravenous